We found that tumor baseline characteristics, including tumor growth rate, CD19 expression, and T cell abundance, greatly influenced tumor-killing pharmacodynamics, tumor evolution, and consequentially, the ideal dosing regimen. The gene discussed is CD19; the disease is neoplasm.